CoChat
Sign Up
Cited by 17Multiple Myeloma Research and TreatmentsMesenchymal stem cell researchHematopoietic Stem Cell Transplantation

Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling

Open access
Wang, Lei, Yi, Weijun, Ma, Li, Lecea, Emily, Hazlehurst, Lori A., Adjeroh, Donald A., Hu, Gangqing·2023·Cancers
DOI 10.3390/cancers15215148PMC PMC10650304
Open this paper in CoChat — free accountOpen PDF

Abstract

Bone marrow mesenchymal stem cells (BM MSCs) play a tumor-supportive role in promoting drug resistance and disease relapse in multiple myeloma (MM). Recent studies have discovered a sub-population of MSCs, known as inflammatory MSCs (iMSCs), exclusive to the MM BM microenvironment and implicated in drug resistance. Through a sophisticated analysis of public expression data from unexpanded BM MSCs, we uncovered a positive association between iMSC signature expression and minimal residual disease. While in vitro expansion generally results in the loss of the iMSC signature, our meta-analysis of additional public expression data demonstrated that cytokine stimulation, including IL1-β and TNF-α, as well as immune cells such as neutrophils, macrophages, and MM cells, can reactivate the signature expression of iMSCs to varying extents. These findings underscore the importance and potential utility of cytokine stimulation in mimicking the gene expression signature of early passage of iMSCs for functional characterizations of their tumor-supportive roles in MM.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15215148

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 57

  1. [2]Chen W.C. Hu G. Hazlehurst L.A. Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors Curr. Opin. Pharmacol. 2020 54 36 43 10.1016/j.coph.2020.08.006 32898723 PMC7770000 · DOI
  2. [3]Diakos C.I. Charles K.A. McMillan D.C. Clarke S.J. Cancer-related inflammation and treatment effectiveness Lancet Oncol. 2014 15 e493 e503 10.1016/S1470-2045(14)70263-3 25281468 · DOI · Paper page
  3. [4]Pinto V. Bergantim R. Caires H.R. Seca H. Guimaraes J.E. Vasconcelos M.H. Multiple Myeloma: Available Therapies and Causes of Drug Resistance Cancers 2020 12 407 10.3390/cancers12020407 32050631 PMC7072128 · DOI
  4. [5]Kumar S. Baizer L. Callander N.S. Giralt S.A. Hillengass J. Freidlin B. Hoering A. Richardson P.G. Schwartz E.I. Reiman A. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee Blood Cancer J. 2022 12 98 10.1038/s41408-022-00695-5 35768410 PMC9243011 · DOI · Paper page
  5. [6]Filippi I. Saltarella I. Aldinucci C. Carraro F. Ria R. Vacca A. Naldini A. Different Adaptive Responses to Hypoxia in Normal and Multiple Myeloma Endothelial Cells Cell. Physiol. Biochem. 2018 46 203 212 10.1159/000488423 29587264 · DOI
  6. [7]Reagan M.R. Ghobrial I.M. Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects Clin. Cancer Res. 2012 18 342 349 10.1158/1078-0432.CCR-11-2212 22065077 PMC3261316 · DOI
  7. [8]Russell K.C. Phinney D.G. Lacey M.R. Barrilleaux B.L. Meyertholen K.E. O’Connor K.C. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment Stem Cells 2010 28 788 798 10.1002/stem.312 20127798 · DOI
  8. [9]Banfi A. Muraglia A. Dozin B. Mastrogiacomo M. Cancedda R. Quarto R. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy Exp. Hematol. 2000 28 707 715 10.1016/S0301-472X(00)00160-0 10880757 · DOI
  9. [12]Alameda D. Saez B. Lara-Astiaso D. Sarvide S. Lasa M. Alignani D. Rodriguez I. Garate S. Vilas A. Paiva B. Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: Transcriptional modulation of the microenvironment Haematologica 2020 105 e470 e473 10.3324/haematol.2019.235135 33054066 PMC7556476 · DOI
  10. [13]Sklavenitis-Pistofidis R. Haradhvala N.J. Getz G. Ghobrial I.M. Inflammatory stromal cells in the myeloma microenvironment Nat. Immunol. 2021 22 677 678 10.1038/s41590-021-00947-9 34017125 · DOI
  11. [14]Sarsenova M. Kim Y. Raziyeva K. Kazybay B. Ogay V. Saparov A. Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells Front. Immunol. 2022 13 1010399 10.3389/fimmu.2022.1010399 36211399 PMC9537745 · DOI
  12. [15]Fernando R.C. Mazzotti D.R. Azevedo H. Sandes A.F. Rizzatti E.G. de Oliveira M.B. Alves V.L.F. Eugenio A.I.P. de Carvalho F. Dalboni M.A. Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism Sci. Rep. 2019 9 1056 10.1038/s41598-018-38314-8 30705326 PMC6355867 · DOI
  13. [16]Garcia-Gomez A. Li T.L. de la Calle-Fabregat C. Rodriguez-Ubreva J. Ciudad L. Catala-Moll F. Godoy-Tena G. Martin-Sanchez M. San-Segundo L. Muntion S. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease Nat. Commun. 2021 12 421 10.1038/s41467-020-20715-x 33462210 PMC7813865 · DOI · Paper page
  14. [18]Garcia-Gomez A. De Las Rivas J. Ocio E.M. Diaz-Rodriguez E. Montero J.C. Martin M. Blanco J.F. Sanchez-Guijo F.M. Pandiella A. San Miguel J.F. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease Oncotarget 2014 5 8284 8305 10.18632/oncotarget.2058 25268740 PMC4226683 · DOI
  15. [19]Umezu T. Imanishi S. Azuma K. Kobayashi C. Yoshizawa S. Ohyashiki K. Ohyashiki J.H. Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis Blood Adv. 2017 1 812 823 10.1182/bloodadvances.2016003251 29296725 PMC5727805 · DOI
  16. [20]Andre T. Meuleman N. Stamatopoulos B. De Bruyn C. Pieters K. Bron D. Lagneaux L. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells PLoS ONE 2013 8 e59756 10.1371/journal.pone.0059756 23555770 PMC3605355 · DOI · Paper page
  17. [21]McNee G. Eales K.L. Wei W. Williams D.S. Barkhuizen A. Bartlett D.B. Essex S. Anandram S. Filer A. Moss P.A. Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma Leukemia 2017 31 373 381 10.1038/leu.2016.187 27400413 PMC5292682 · DOI
  18. [22]Heinemann L. Mollers K.M. Ahmed H.M.M. Wei L. Sun K. Nimmagadda S.C. Frank D. Baumann A. Poos A.M. Dugas M. Inhibiting PI3K-AKT-mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells Front. Oncol. 2022 12 874325 10.3389/fonc.2022.874325 35795041 PMC9251191 · DOI · Paper page
  19. [23]Li B. Xu H. Han H. Song S. Zhang X. Ouyang L. Qian C. Hong Y. Qiu Y. Zhou W. Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis Oncogene 2018 37 5508 5519 10.1038/s41388-018-0359-0 29895968 · DOI
  20. [24]Wiese D.M. Wood C.A. Ford B.N. Braid L.R. Cytokine Activation Reveals Tissue-Imprinted Gene Profiles of Mesenchymal Stromal Cells Front. Immunol. 2022 13 917790 10.3389/fimmu.2022.917790 35924240 PMC9341285 · DOI
  21. [25]Rubinstein-Achiasaf L. Morein D. Ben-Yaakov H. Liubomirski Y. Meshel T. Elbaz E. Dorot O. Pichinuk E. Gershovits M. Weil M. Persistent Inflammatory Stimulation Drives the Conversion of MSCs to Inflammatory CAFs That Promote Pro-Metastatic Characteristics in Breast Cancer Cells Cancers 2021 13 1472 10.3390/cancers13061472 33806906 PMC8004890 · DOI
  22. [26]Carrero R. Cerrada I. Lledo E. Dopazo J. Garcia-Garcia F. Rubio M.P. Trigueros C. Dorronsoro A. Ruiz-Sauri A. Montero J.A. IL1beta induces mesenchymal stem cells migration and leucocyte chemotaxis through NF-kappaB Stem Cell Rev. Rep. 2012 8 905 916 10.1007/s12015-012-9364-9 22467443 PMC3412085 · DOI
  23. [27]Guilloton F. Caron G. Menard C. Pangault C. Ame-Thomas P. Dulong J. De Vos J. Rossille D. Henry C. Lamy T. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes Blood 2012 119 2556 2567 10.1182/blood-2011-08-370908 22289889 · DOI
  24. [28]Jin P. Zhao Y. Liu H. Chen J. Ren J. Jin J. Bedognetti D. Liu S. Wang E. Marincola F. Interferon-gamma and Tumor Necrosis Factor-alpha Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype Sci. Rep. 2016 6 26345 10.1038/srep26345 27211104 PMC4876328 · DOI
  25. [29]Lerrer S. Liubomirski Y. Bott A. Abnaof K. Oren N. Yousaf A. Korner C. Meshel T. Wiemann S. Ben-Baruch A. Co-Inflammatory Roles of TGFbeta1 in the Presence of TNFalpha Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells Front. Immunol. 2017 8 479 10.3389/fimmu.2017.00479 28553282 PMC5425596 · DOI
  26. [30]Gregoire M. Guilloton F. Pangault C. Mourcin F. Sok P. Latour M. Ame-Thomas P. Flecher E. Fest T. Tarte K. Neutrophils trigger a NF-kappaB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas Oncotarget 2015 6 16471 16487 10.18632/oncotarget.4106 26158216 PMC4599283 · DOI
  27. [31]Espagnolle N. Balguerie A. Arnaud E. Sensebe L. Varin A. CD54-Mediated Interaction with Pro-inflammatory Macrophages Increases the Immunosuppressive Function of Human Mesenchymal Stromal Cells Stem Cell Rep. 2017 8 961 976 10.1016/j.stemcr.2017.02.008 28330617 PMC5390105 · DOI
  28. [32]Dotterweich J. Schlegelmilch K. Keller A. Geyer B. Schneider D. Zeck S. Tower R.J. Ebert R. Jakob F. Schutze N. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease Bone 2016 93 155 166 10.1016/j.bone.2016.08.006 27519972 · DOI
  29. [34]Dziadowicz S. Wang L. Akhter H. Aesoph D. Sharma T. Adjeroh D. Hazlehurst L. Hu G. Bone Marrow Stroma-induced Transcriptome and Regulome Signatures of Multiple Myeloma Cancers 2022 14 927 10.3390/cancers14040927 35205675 PMC8870223 · DOI
  30. [35]Jiang P. Zhang Y. Ru B.B. Yang Y. Vu T. Paul R. Mirza A. Altan-Bonnet G. Liu L.R. Ruppin E. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels Nat. Methods 2021 18 1181 1191 10.1038/s41592-021-01274-5 34594031 PMC8493809 · DOI
  31. [36]Liberzon A. Birger C. Thorvaldsdottir H. Ghandi M. Mesirov J.P. Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection Cell Syst. 2015 1 417 425 10.1016/j.cels.2015.12.004 26771021 PMC4707969 · DOI · Paper page
  32. [37]Choi H. Kim Y. Kang D. Kwon A. Kim J. Kim J.M. Park S.S. Kim Y.J. Min C.K. Kim M. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma Cell Proliferat. 2020 53 e12819 10.1111/cpr.12819 PMC7260074 32372504 · DOI
  33. [38]Wang Z. Li X. Yang J. Gong Y. Zhang H. Qiu X. Liu Y. Zhou C. Chen Y. Greenbaum J. Single-cell RNA sequencing deconvolutes the in vivo heterogeneity of human bone marrow-derived mesenchymal stem cells Int. J. Biol. Sci. 2021 17 4192 4206 10.7150/ijbs.61950 34803492 PMC8579438 · DOI
  34. [39]Vijay J. Gauthier M.F. Biswell R.L. Louiselle D.A. Johnston J.J. Cheung W.A. Belden B. Pramatarova A. Biertho L. Gibson M. Single-cell analysis of human adipose tissue identifies depot- and disease-specific cell types Nat. Metab. 2020 2 97 109 10.1038/s42255-019-0152-6 32066997 PMC7025882 · DOI
  35. [40]Lara-Castro C. Fu Y. Chung B.H. Garvey W.T. Adiponectin and the metabolic syndrome: Mechanisms mediating risk for metabolic and cardiovascular disease Curr. Opin. Lipidol. 2007 18 263 270 10.1097/MOL.0b013e32814a645f 17495599 · DOI
  36. [41]Li N. Zhou L. Xie W.L. Zeng D.Y. Cai D.Q. Wang H.Y. Zhou C.R. Wang J. Li L.H. Alkaline phosphatase enzyme-induced biomineralization of chitosan scaffolds with enhanced osteogenesis for bone tissue engineering Chem. Eng. J. 2019 371 618 630 10.1016/j.cej.2019.04.017 · DOI
  37. [42]Zhytnik L. Maasalu K. Pashenko A. Khmyzov S. Reimann E. Prans E. Koks S. Martson A. COL1A1/2 Pathogenic Variants and Phenotype Characteristics in Ukrainian Osteogenesis Imperfecta Patients Front. Genet. 2019 10 722 10.3389/fgene.2019.00722 31447884 PMC6696896 · DOI
  38. [43]Akiyama H. Kim J.E. Nakashima K. Balmes G. Iwai N. Deng J.M. Zhang Z. Martin J.F. Behringer R.R. Nakamura T. Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors Proc. Natl. Acad. Sci. USA 2005 102 14665 14670 10.1073/pnas.0504750102 16203988 PMC1239942 · DOI
  39. [44]Liu C.F. Lefebvre V. The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis Nucleic Acids Res. 2015 43 8183 8203 10.1093/nar/gkv688 26150426 PMC4787819 · DOI
  40. [45]Ohlund D. Handly-Santana A. Biffi G. Elyada E. Almeida A.S. Ponz-Sarvise M. Corbo V. Oni T.E. Hearn S.A. Lee E.J. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer J. Exp. Med. 2017 214 579 596 10.1084/jem.20162024 28232471 PMC5339682 · DOI · Paper page
  41. [46]Elyada E. Bolisetty M. Laise P. Flynn W.F. Courtois E.T. Burkhart R.A. Teinor J.A. Belleau P. Biffi G. Lucito M.S. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts Cancer Discov. 2019 9 1102 1123 10.1158/2159-8290.CD-19-0094 31197017 PMC6727976 · DOI · Paper page
  42. [47]Kieffer Y. Hocine H.R. Gentric G. Pelon F. Bernard C. Bourachot B. Lameiras S. Albergante L. Bonneau C. Guyard A. Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer Cancer Discov. 2020 10 1330 1351 10.1158/2159-8290.CD-19-1384 32434947 · DOI · Paper page
  43. [48]Nicolas A.M. Pesic M. Engel E. Ziegler P.K. Diefenhardt M. Kennel K.B. Buettner F. Conche C. Petrocelli V. Elwakeel E. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer Cancer Cell 2022 40 168 184.e113 10.1016/j.ccell.2022.01.004 35120600 · DOI · Paper page
  44. [49]Kumar S. Paiva B. Anderson K.C. Durie B. Landgren O. Moreau P. Munshi N. Lonial S. Blade J. Mateos M.V. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Lancet Oncol. 2016 17 e328 e346 10.1016/S1470-2045(16)30206-6 27511158 · DOI · Paper page
  45. [50]Ding H. Xu J. Lin Z. Huang J. Wang F. Yang Y. Cui Y. Luo H. Gao Y. Zhai X. Minimal residual disease in multiple myeloma: Current status Biomark. Res. 2021 9 75 10.1186/s40364-021-00328-2 34649622 PMC8515655 · DOI
  46. [53]Todoerti K. Lisignoli G. Storti P. Agnelli L. Novara F. Manferdini C. Codeluppi K. Colla S. Crugnola M. Abeltino M. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease Exp. Hematol. 2010 38 141 153 10.1016/j.exphem.2009.11.009 19963035 · DOI
  47. [54]Garderet L. Mazurier C. Chapel A. Ernou I. Boutin L. Holy X. Gorin N.C. Lopez M. Doucet C. Lataillade J.J. Mesenchymal stem cell abnormalities in patients with multiple myeloma Leuk. Lymphoma 2007 48 2032 2041 10.1080/10428190701593644 17917971 · DOI
  48. [55]Lemaitre L. Hamaidia M. Descamps J.G. Do Souto Ferreira L. Joubert M.V. Gadelorge M. Avet-Loiseau H. Justo A. Reina N. Deschaseaux F. Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth Blood Adv. 2022 6 672 678 10.1182/bloodadvances.2020003704 34714910 PMC8791574 · DOI
  49. [56]Morohashi H. Miyawaki T. Nomura H. Kuno K. Murakami S. Matsushima K. Mukaida N. Expression of Both Types of Human Interleukin-8 Receptors on Mature Neutrophils, Monocytes, and Natural-Killer-Cells J. Leukocyte Biol. 1995 57 180 187 10.1002/jlb.57.1.180 7829970 · DOI
  50. [57]Zhou Y. Zhou B. Pache L. Chang M. Khodabakhshi A.H. Tanaseichuk O. Benner C. Chanda S.K. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets Nat. Commun. 2019 10 1523 10.1038/s41467-019-09234-6 30944313 PMC6447622 · DOI · Paper page
  51. [58]Baumgart S.J. Najafova Z. Hossan T. Xie W. Nagarajan S. Kari V. Ditzel N. Kassem M. Johnsen S.A. CHD1 regulates cell fate determination by activation of differentiation-induced genes Nucleic Acids Res. 2017 45 7722 7735 10.1093/nar/gkx377 28475736 PMC5570082 · DOI
  52. [59]Wong A.H. Shin E.M. Tergaonkar V. Chng W.J. Targeting NF-kappaB Signaling for Multiple Myeloma Cancers 2020 12 2203 10.3390/cancers12082203 32781681 PMC7463546 · DOI · Paper page
  53. [60]De Jong M.M.E. Fokkema C. Papazian N. van Heusden T. Vermeulen M. Tahri S. Hoogenboezem R. van Duin M. van de Woestijne P. Langerak A. Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma Blood 2022 140 4181 4182 10.1182/blood-2022-166339 · DOI
  54. [61]Meads M.B. Hazlehurst L.A. Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance Clin. Cancer Res. 2008 14 2519 2526 10.1158/1078-0432.CCR-07-2223 18451212 · DOI
  55. [62]De Jong M. Fokkema C. Papazian N. van Heusden T. Vermeulen M. Hoogenboezem R. van Beek G. Tahri S. Sanders M.A. van de Woestijne P. An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich microenvironment in multiple myeloma bioRxiv 2023 10.1101/2023.03.03.530773 38600356 · DOI
  56. [63]Holthof L.C. van der Schans J.J. Katsarou A. Poels R. Gelderloos A.T. Drent E. Van Hal-van Veen S.E. Li F.Z. Zweegman S. van de Donk N.W.C.J. Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis Clin. Cancer Res. 2021 27 3793 3803 10.1158/1078-0432.CCR-20-2188 33883175 · DOI
  57. [64]Dhodapkar K.M. Cohen A.D. Kaushal A. Garfall A.L. Manalo R.J. Carr A.R. McCachren S.S. Stadtmauer E.A. Lacey S.F. Melenhorst J.J. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma Blood Cancer Discov. 2022 3 490 501 10.1158/2643-3230.BCD-22-0018 36026513 PMC9627239 · DOI

Cited by

Sorted by citations

Authors
Wang, L., Yi, W., Ma, L., Lecea, E., Hazlehurst, L. A., Adjeroh, D. A., & Hu, G.
Affiliations
West Virginia University (US)
Corresponding author
Hu, Gangqing
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2023-10-26
Volume
15
Issue
21
Pages
5148
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers15215148
PMC
PMC10650304
OpenAlex
W4388199350
Cited by
17
References
7
Citations by year
2026: 10 · 2025: 5 · 2024: 2
FWCI
3.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • NIH NIGMS (P20 GM103434, U54 GM-104942, 2P20 GM121322, 2125872)
  • NSF (P20 GM103434, U54 GM-104942, 2P20 GM121322, 2125872)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
multiple myeloma, bone marrow mesenchymal stem cells, tumor microenvironment, minimal residual disease, drug resistance, gene expression signatures, in vitro expansion, IL-1β, TNF-α, cytokine induction, neutrophils, macrophages, in vitro disease model

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review